The Influence of Soy Isoflavones and Soy Isoflavones with Inulin on Kidney Morphology, Fatty Acids, and Associated Parameters in Rats with and without Induced Diabetes Type 2.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI, [2000-

Isoflavones*/pharmacology ; Inulin*/pharmacology ; Inulin*/administration & dosage ; Kidney*/drug effects ; Kidney*/pathology ; Kidney*/metabolism ; Rats, Sprague-Dawley* ; Diabetes Mellitus, Experimental*/drug therapy ; Diabetes Mellitus, Type 2*/drug therapy ; Diabetes Mellitus, Type 2*/pathology ; Diabetes Mellitus, Type 2*/metabolism ; Fatty Acids*/metabolism ; Glycine max*/chemistry; Animals ; Male ; Rats ; Blood Glucose/metabolism ; Blood Glucose/drug effects ; Diet, High-Fat/adverse effects ; Hypoglycemic Agents/pharmacology ; Hypoglycemic Agents/therapeutic use

Diabetes mellitus resulting from hyperglycemia stands as the primary cause of diabetic kidney disease. Emerging evidence suggests that plasma concentrations of soy isoflavones, substances with well-established antidiabetic properties, rise following supplemental inulin administration. The investigation encompassed 36 male Sprague-Dawley (SD) rats segregated into two cohorts: non-diabetic and diabetic, induced with type 2 diabetes (high-fat diet + two intraperitoneal streptozotocin injections). Each cohort was further divided into three subgroups (n = 6): control, isoflavone-treated, and isoflavone plus inulin-treated rats. Tail blood glucose and ketone levels were gauged. Upon termination, blood samples were drawn directly from the heart for urea, creatinine, and HbA1c/HbF analyses. One kidney per rat underwent histological (H-E) and immunohistochemical assessments (anti-AQP1, anti-AQP2, anti-AVPR2, anti-SLC22A2, anti-ACC-alpha, anti-SREBP-1). The remaining kidney underwent fatty acid methyl ester analysis. Results unveiled notable alterations in water intake, body and kidney mass, kidney morphology, fatty acids, AQP2, AVPR2, AcetylCoA, SREBP-1, blood urea, creatinine, and glucose levels in control rats with induced type 2 diabetes. Isoflavone supplementation exhibited favorable effects on plasma urea, plasma urea/creatinine ratio, glycemia, water intake, and kidney mass, morphology, and function in type 2 diabetic rats. Additional inulin supplementation frequently modulated the action of soy isoflavones.

J Proteomics Bioinform. 2015 Oct;Suppl 14:. (PMID: 26778897)
Endocrinology. 2003 Aug;144(8):3315-20. (PMID: 12865308)
J Biol Chem. 2002 May 24;277(21):18919-27. (PMID: 11875060)
Diabetologia. 2007 May;50(5):906-12. (PMID: 17333103)
Am J Physiol Renal Physiol. 2001 Apr;280(4):F715-26. (PMID: 11249863)
Kidney Int. 2014 Aug;86(2):350-7. (PMID: 24646860)
Endocrinology. 2015 Mar;156(3):777-88. (PMID: 25514088)
J Membr Biol. 2014 Aug;247(8):675-83. (PMID: 24906870)
Lipids Health Dis. 2020 Apr 17;19(1):77. (PMID: 32303226)
J Anat. 2008 Jun;212(6):845-52. (PMID: 18510511)
Diabetologia. 1997 Jul;40(7):802-9. (PMID: 9243101)
Metabolites. 2022 Oct 03;12(10):. (PMID: 36295842)
PeerJ. 2022 Sep 20;10:e13932. (PMID: 36157062)
Diabetes Metab Res Rev. 1999 Nov-Dec;15(6):412-26. (PMID: 10634967)
Diabetol Int. 2015 May 14;7(1):53-58. (PMID: 30603243)
Nat Med. 2015 Jan;21(1):37-46. (PMID: 25419705)
Am J Physiol. 1997 Dec;273(6):F949-53. (PMID: 9435684)
J Biol Chem. 2022 Oct;298(10):102401. (PMID: 35988648)
Heliyon. 2020 Jan 09;6(1):e03192. (PMID: 31956716)
Diabetes. 1994 Aug;43(8):1046-51. (PMID: 8039599)
Diabetes. 2003 Aug;52(8):1958-66. (PMID: 12882911)
Int J Mol Sci. 2021 Aug 12;22(16):. (PMID: 34445384)
Am J Physiol Endocrinol Metab. 2010 Dec;299(6):E1066-75. (PMID: 20923962)
Bio Protoc. 2019 Dec 20;9(24):. (PMID: 31867411)
J Biol Chem. 1957 May;226(1):497-509. (PMID: 13428781)
Front Biosci. 2008 Jan 01;13:2660-73. (PMID: 17981741)
J Microsc Ultrastruct. 2015 Jul-Sep;3(3):108-119. (PMID: 30023190)
Toxicol Lett. 2010 Jul 15;196(3):142-53. (PMID: 20381596)
Biochem Pharmacol. 2002 Jul 15;64(2):185-90. (PMID: 12123738)
Sci Rep. 2022 Dec 2;12(1):20827. (PMID: 36460694)
Pharmacol Toxicol. 2003 Sep;93(3):116-22. (PMID: 12969435)
Lab Invest. 2004 Apr;84(4):452-64. (PMID: 14767489)
Am J Physiol Renal Physiol. 2019 Dec 1;317(6):F1450-F1461. (PMID: 31566426)
Histol Histopathol. 2019 Oct;34(10):1131-1140. (PMID: 30958562)
Am J Pathol. 1982 Apr;107(1):92-7. (PMID: 7065126)
Diabetologia. 2016 Jun;59(6):1318-28. (PMID: 26995650)
Nutr Res Pract. 2007 Winter;1(4):266-72. (PMID: 20368949)
J Forensic Sci. 2013 Jan;58 Suppl 1:S94-8. (PMID: 22971043)
Adv Nutr. 2017 Sep 15;8(5):705-717. (PMID: 28916571)
Theranostics. 2020 Aug 20;10(23):10415-10433. (PMID: 32929357)
Am J Physiol Endocrinol Metab. 2009 Jul;297(1):E28-37. (PMID: 19066317)
Int J Mol Sci. 2020 Dec 28;22(1):. (PMID: 33379327)
Diabetologia. 2007 Dec;50(12):2580-90. (PMID: 17952403)
J Nutr Biochem. 2002 Nov;13(11):671-677. (PMID: 12550064)
Biosci Biotechnol Biochem. 2007 Oct;71(10):2451-7. (PMID: 17928702)
Food Funct. 2013 Feb;4(2):200-12. (PMID: 23160185)
Biochem Biophys Res Commun. 1998 Aug 28;249(3):704-8. (PMID: 9731201)
Int J Mol Sci. 2016 Nov 09;17(11):. (PMID: 27834856)
Cell Metab. 2017 Sep 5;26(3):576. (PMID: 28877461)
Oncotarget. 2015 May 30;6(15):13036-48. (PMID: 25948777)
Open Life Sci. 2023 Feb 10;18(1):20220560. (PMID: 36820212)
Lancet. 2020 Feb 29;395(10225):709-733. (PMID: 32061315)
Physiol Behav. 1991 Jan;49(1):189-99. (PMID: 2017474)
Nephrology (Carlton). 2005 Feb;10(1):63-72. (PMID: 15705184)
J Am Soc Nephrol. 2001 Apr;12(4):779-790. (PMID: 11274239)
Am J Clin Nutr. 2007 Sep;86(3):775-80. (PMID: 17823445)
Nutr Rev. 2003 Jun;61(6 Pt 1):189-203. (PMID: 12903829)
Molecules. 2016 May 03;21(5):. (PMID: 27153053)
Diabetes Metab J. 2020 Aug;44(4):581-591. (PMID: 31701696)
Am J Pathol. 2013 Sep;183(3):735-44. (PMID: 23867797)
World J Diabetes. 2013 Dec 15;4(6):245-55. (PMID: 24379914)
Lab Invest. 1990 Jan;62(1):108-13. (PMID: 2296156)
World J Gastroenterol. 2015 Jan 28;21(4):1099-107. (PMID: 25632182)
J Pharm Biomed Anal. 2019 Mar 20;166:30-39. (PMID: 30599279)
Kidney Int. 2003 Jun;63(6):2152-61. (PMID: 12753302)
Br J Nutr. 2002 May;87 Suppl 2:S255-9. (PMID: 12088526)
World J Diabetes. 2021 May 15;12(5):524-540. (PMID: 33995842)
J Zhejiang Univ Sci B. 2018 Jul;19(7):559-569. (PMID: 29971994)
Exp Diabetes Res. 2008;2008:704045. (PMID: 19132099)
Cell Mol Gastroenterol Hepatol. 2021;12(3):983-1000. (PMID: 33940221)
J Nutr. 1995 Mar;125(3 Suppl):594S-597S. (PMID: 7884539)
Food Chem. 2022 Apr 16;374:131493. (PMID: 34802809)
Endocrinology. 2010 Jul;151(7):3026-37. (PMID: 20484465)
Carcinogenesis. 2010 Sep;31(9):1509-15. (PMID: 20595235)
Cell Metab. 2017 Mar 7;25(3):713-726. (PMID: 28190774)
BMC Med. 2021 Dec 9;19(1):313. (PMID: 34879839)
Diabetologia. 2015 May;58(5):886-99. (PMID: 25725623)
J Am Soc Nephrol. 2017 Apr;28(4):1023-1039. (PMID: 28143897)

MB-167-165/16; WLA-167-02/S/16/2023 This research was funded by an internal grant from the Pomeranian Medical University for young researchers (Młody Badacz), No MB-167-165/16 and was also financed from funds for re-search and development (statutory activity of the Pomeranian Medical Univer

Keywords: diabetes; fatty acids; inulin; kidney; morphology; soy isoflavones

0 (Isoflavones)
9005-80-5 (Inulin)
0 (Fatty Acids)
0 (Blood Glucose)
0 (Hypoglycemic Agents)

Date Created: 20240525 Date Completed: 20240525 Latest Revision: 20240527

20240527

PMC11121859

10.3390/ijms25105418

38791455